Introduction
============

Neurodevelopmental needs are clinically important but often overlooked co-morbidities in Duchenne muscular dystrophy (DMD), the most common X-linked neuromuscular disease that affects 1 in 5000 live births[@ref1]. Autism spectrum[@ref2]^,^[@ref3], attention-deficit hyperactivity[@ref3]^,^[@ref4]^,^[@ref5], and obsessive compulsive disorders[@ref3] are 4 times more common in DMD than in typically developing children. Developmental delay---particularly expressive language delay---is a core neurological symptom in DMD, and was described as early as Duchenne himself 150 years ago[@ref6]^,^[@ref7]. Over the past several years, there has been increasing recognition of the higher-order cognitive skills that are affected in DMD. These include working memory and executive function deficits[@ref8], academic under-performance[@ref9], and increased utilization of school resources[@ref10]. As the life-expectancy in DMD has increased tremendously with survival into the third decade of life, it is increasingly important to identify potential strategies for early and improved screening of neurodevelopmental needs in DMD, and to evaluate pragmatic interventions to improve cognitive health[@ref11]. Most importantly, neurodevelopmental disorders and cognitive disabilities have a significant negative impact on the quality-of-life on a daily basis, and affects overall health maintenance.

Dystrophin plays a critical role in brain function[@ref12]. There are several brain-specific dystrophin isoforms, including the full-length dystrophin (dp427), and shorter dystrophin isoforms (dp260, dp140, and dp71) generated by tissue-specific promoters. The following are the unique first exons for the shorter dystrophin isoforms: exon 30 for dp260, exon 45 for dp140, and exon 63 for dp71[@ref13]^,^[@ref14]. In humans, dystrophin is highly expressed by neurons in the cerebellum, the cerebral cortex, and hippocampus. In neurons, dystrophin localizes within the pre-synaptic density (PSD95), a region that is important for dendritic spine formation and synaptic function[@ref15].

Few investigators suggest a differential vulnerability in the severity of cognitive involvement when DMD mutations are between exons 45-50, suggesting a critical role for the dystrophin dp140 isoform in cognitive function[@ref16]^,^[@ref17]. Not only do individuals with mutations between DMD exons 45-50 have lower intellectual capacity and impaired information processing compared to individuals with DMD mutations in exons 1-44, they also have smaller total brain volume and gray matter volume[@ref18].

We systematically evaluated the prevalence of neurodevelopmental needs, stratified based on DMD mutation location, in a large prospectively followed cohort of 204 boys between ages 4 to less than 9 years with DMD. These 204 boys were recruited as part of the DMD Natural History Study (DHNS) conducted by the Cooperative International Neuromuscular Research Group (CINRG)[@ref19]. We describe the neurodevelopmental needs in this young cohort at study enrollment as reported by the parent or primary care-giver.

We present data that supports that young boys with DMD have a high prevalence of neurodevelopmental needs as reported by parent or care-giver. Further, boys with DMD mutations between exons 45-50 reported higher cognitive problems. There was no relationship between neurodevelopmental needs and glucocorticoid use. We conclude that there is an unmet, critical medical need in DMD to develop pragmatic solutions for early detection and intervention of neurodevelopmental needs during a window of neurodevelopmental plasticity.

Methods
=======

The study was conducted in accordance with the Declaration of Helsinki (2000) and the principles of Good Clinical Practice according to the International Conference on Harmonization. All study participants provided written consent prior to study enrollment. Each site has its IRB which approved the study. At Children's National Health System, the institutional IRB approved the study (\#0159)

**[Study participants]{.ul}**

The study was conducted in accordance with the World Medical Association Declaration of Helsinki. All study participants provided written consent prior to study enrollment. The study was approved by the ethical review committee at each of the participating sites. Study subjects were recruited from academic institutions within the United States and at other international sites between the years 2006 and 2014. Subjects in this data analysis were part of the DNHS, a 10-year multi-center, international, prospective longitudinal study of DMD (ClinicalTrials.gov NCT00468832). A detailed study description is available as described in McDonald et al.[@ref19]. We chose to evaluate the 204 participants who were between age 4 to less than 9 years in order to identify neurodevelopmental needs in early childhood. Briefly, study participants were evaluated every three months during the first year of study enrollment, every 6 months during the second year of enrollment, and annually thereafter. The assessments performed at each study visit included physical examination, reviews-of-body systems, medication history, muscle strength quantification, functional measurements, and quality-of-life questionnaires completed by the parent or primary care-giver.

**[Dystrophin isoform (dp140) assignment]{.ul}**

Information regarding DMD mutation was available in 152 of the 204 participants. The anonymized study participants' genetic information including exon boundaries of the DMD mutation was reviewed by a genetic counselor. We categorized mutations upstream of DMD exon 44 as dp140+, and those with mutations downstream of DMD exon 51 were categorized as dp140 negative. All subjects whose mutation fell between DMD exon boundaries 45 to 50 were assigned into the dp140 intermediate group. The categorization of study participants is summarized in Figure 1. There were 53 subjects in the dystrophin dp140+ category, 52 subjects in the dystrophin dp140- category, and 48 subjects in the dystrophin dp140 intermediate category.

Categorization of participants based on DMD exon boundary.Fig 1

**[Evaluation of neurodevelopmental needs]{.ul}**

We evaluated several responses that relate to neurodevelopmental needs from the quality-of-life questions completed by the parent or primary care-giver. These domains focused on twelve neurodevelopmental items, including reports of speech delay, cognitive and learning impairments, and were collected as part of the review of participant medical and developmental history. Reports of study participants attending individual or group therapy, being under-the-care of a psychiatrist or psychologist, and four assessments of school-related activities, (full- or part-time special education, utilization of class-room services, and being on an individualized educational plan (IEP)) were also collected. An IEP refers to the special education, services and additional accommodations that are made available to a child with disability that allow them to attain educational goals and academic milestones. Lastly, pediatric quality-of-life data were captured from all study participants. Here we report the physical, social, emotional, and school sub-scores, along with the total score, from the Pediatric Quality of Life Inventory, version 4 (PedsQoL)[@ref20]. The Pediatric Quality of Life (PedsQL) Inventory is a proxy-report measure designed to measure core health dimensions in children from 5 to 17 years old. The measure consists of 23 items in four scales: physical functioning, emotional functioning, social functioning, and school functioning.

**[Statistical Analysis]{.ul}**

Descriptions of the study cohort are provided either as frequencies (N and %) or as summary statistics (N, mean, standard deviation (SD), median, minimum, and maximum) as appropriate for each domain type. Each domain was first compared independently among the three dystrophin dp140 mutation categories. These statistical comparisons were performed using one-way analysis of variance or Kruskal-Wallis tests for continuous outcomes, and Fisher's exact tests for categorical outcomes. Those neurodevelopmental or cognitive domains showing evidence of a significant relationship with predicted dystrophin dp140 isoform expression were further analyzed using logistic regression. In each logistic regression model, neurodevelopmental or cognitive domain (dichotomous yes/no response) was the dependent variable, and dystrophin dp140 category was the predictive variable. Dystrophin dp140(-) category was considered the reference group, and an additional test comparing the dystrophin dp140(+) and dystrophin dp140 intermediate group was also performed.

In order to assure that neither age nor glucocorticoid use were confounding factors in our data analysis, we compared outcomes between glucocorticoid use (yes/no at baseline visit), and between 1-year age intervals.

For the statistical comparison of responses obtained for the twelve neurodevelopment-related outcomes, we excluded those that answered "Don't know" or "Not applicable" due to the ambiguity of the response. The rationale to exclude these responses was that we were not able to meaningfully interpret the response, especially for the school-related resources. The "not applicable" response in this setting could be due to the child not attending school, or lack of neurodevelopmental needs, and therefore not needing school services.

All statistical analyses were performed on the data collected at the first study enrollment visit. The significance level for all statistical tests was set at 0.05. Data was analyzed using Stata V15 software (College Station, TX).

Results
=======

**[Study characteristics and demographic information]{.ul}**

A total of 204 participants from North America, Europe, Israel, Australia, and India were included in this young cohort of the DNHS. To determine equity in access to health care, we note that most of the study participants were from developed countries (n=176), whereas 28 participants were from India, a developing country. The mean age of the study participants was 6.4 years (range, 4.0 -- 8.9 years). The majority of the study participants identified their race as Caucasian (72.6%), with 17.7% identifying as Asian, 3.5% as Other, 1.0% as Pacific Islander, and 0.5% as Black (0.5%). A minority of the participants (4.9%) reported their race as unknown. Ethnicity was reported as non-Hispanic by 93% of participants and as Hispanic by 7.8% participants. These demographic characteristics, along with anthropometric measures, are summarized in Table 1.

Table 1Summarizes the demographic and anthropometric details of the study participants.CharacteristicTotal cohortDP140 NegativeDP140 IntermediateDP140 PositiveP-value comparing DP140 groupsN (%)N (%)N (%)N (%)Mean ± SDMean ± SDMean ± SDMean ± SDMedian (min, max)Median (min, max)Median (min, max)Median (min, max)Age (years)2045248530.996.4 ± 1.46.5 ± 1.46.5 ± 1.36.5 ± 1.46.4 (4.0, 8.9)6.6 (4.0, 8.9)6.4 (4.3, 8.9)6.2 (4.1, 8.9)Weight (kg)2045248530.6722.0 ± 5.722.3 ± 5.921.4 ± 6.222.4 ± 5.720.7 (13.4, 48.2)21.0 (13.4, 37.1)20.0 (15.0, 48.2)21.8 (13.5, 41.0)Calculated height (cm)203\*5148530.85116.6 ± 9.2116.6 ± 9.2117.0 ± 8.9116.0 ± 9.6115.7 (95.4, 139.9)117,8 (96.9, 135.4)116.3 (99.9, 139.9)114.9 (95.4, 134.3)Race0.25Caucasian148 (72.6%)39 (75.0%)31 (64.5%)39 (73.6%)Black1 (0.5%)0 (0.0%)1 (2.1%)0 (0.0%)Pacific Isl.2 (1.0%)0 (0.0%)0 (0.0%)2 (3.8%)Asian36 (17.7%)11 (21.2%)13 (27.1%)6 (11.3%)Other7 (3.4%)1 (1.9%)1 (2.1%)4 (7.6%)Unknown10 (4.9%)1 (1.9%)2 (4.2%)2 (3.8%)Ethnicity0.22Non-Hispanic188 (93.2%)47 (90.4%)45 (94.8%)52 (98.1%)Hispanic16 (7.8%)5 (9.6%)3 (6.3%)1 (1.9%)

\*Height was not reported in one participant during the first year of study.

**[Study subjects and their treatment with oral glucocorticoids]{.ul}**

Sixty-one percent of participants (n=124) were on oral glucocorticoids at the time of their baseline study visit (Table 2). Of these 124 participants, 79 participants (39%) were either on prednisone or prednisolone, and 44 participants (22%) were on deflazacort. One participant reported glucocorticoid use but did not indicate the name of the medication being prescribed. The duration of cumulative use of glucocorticoid ranged from no previous use to 4.5 years.

Table 2Summarizes the glucocorticoid use in study participants.Total cohortDP140 NegativeDP140 IntermediateDP140 PositiveP-value comparing DP140 groupsN (%)N (%)N (%)N (%)Mean ± SDMean ± SDMean ± SDMean ± SDMedian (min, max)Median (min, max)Median (min, max)Median (min, max)Is the study participant taking steroids at baseline0.39Yes124 (60.8%)29 (55.8%)33 (68.8%)34 (64.2%)No80 (39.2%)23 (44.2%)15 (31.3%)19 (35.9%)Total lifetime steroid use at baseline (days)2045248530.34288 ± 382291 ± 390241 ± 340355 ± 42395 (0, 1665)53 (0, 1182)95 (0, 1665)208 (0, 1579)Type of steroid taken\*0.92None80 (39.4%)23 (44.3%)15 (31.9%)19 (35.9%)Prednisone48 (23.7%)12 (23.1%)13 (27.7%)15 (28.3%)Deflazacort44 (21.7%)11 (21.2%)11 (23.4%)11 (20.8%)Prednisolone31 (15.3%)6 (11.5%)8 (17.0%)8 (15.1%)

**[Care-giver reported neurodevelopmental needs]{.ul}**

The response completion of neurodevelopmental needs identified by the care-giver was variable depending on the question, ranging from 168 to 174 respondents (82 - 85%) of the 204 participants at the first study visit. The following neurodevelopmental needs were most commonly reported: speech delay (33%), mild developmental delay (24%), significant behavioral problems (16.5%), language impairment (14.5%), and learning disability (14%). Other neurodevelopmental needs reported by the parent or primary care-giver included attention-deficit hyperactivity disorder (5%) and autism spectrum disorder (3%). Summaries of responses from the entire cohort are shown in Supplementary Table 1.

With regards to therapy services, most respondents had not received any (Supplemental Table 2). With regards to utilization of school-based resources at the first study visit, of the 169 respondents, an equal number of participants were on an IEP (n= 65) as not on an IEP (n=65) (Supplemental Table 3). Thirty-six participants (22%) reported that an IEP was not applicable in their child's case, though thirteen of these participants (36%) were under the age of 5 years. The commencement of school is age 5 years in developed countries. These thirty-six participants were excluded from the subsequent analyses since no further information was available from them. Sixty-three percent (n=106) reported receiving no services in the school compared to 27% (n=46) receiving classroom services (Supplemental Table 3). Of those not receiving classroom services, 10% (n=17) responded that they were not applicable and 1% (n=2) did not know whether their child was receiving any services. Fourteen of the "no responses" and 10 of the "not applicable" responses were in participants under the age of 5 years.

When participants were asked whether they had been evaluated by a mental health provider (psychiatrist or psychologist), most of them participants had not been (Supplemental Tables 4, 5).

When study participants were stratified based on 1-year age intervals at study enrollment, parent or primary care-giver of participants identified between boys between 7 to 8 years of age as having more behavioral, neurodevelopmental and cognitive needs (significant behavioral problems, speech delay, language impairment, learning disability) (Table 3). Similarly, IEP and utilization of services in the classroom were more often reported in participants 7 years to 8 years of age (Table 4). Of the 169 respondents, 141 (83%) report that they had never been evaluated by a psychologist.

Table 3Summarizes neurodevelopmental challenges based on age groups.Have you ever been diagnosed with-Age groupNoYesDon\'t knowP-value\*Significant behavioral problems4 to \<525210.595 to \<636626 to \<727607 to \<829818 to \<92560Depression4 to \<527010.745 to \<644006 to \<733007 to \<836118 to \<93100Autism4 to \<527100.215 to \<642026 to \<732107 to \<835308 to \<93000Speech delay4 to \<5161200.155 to \<6281336 to \<724907 to \<8211708 to \<92560Language impairment4 to \<523410.205 to \<637436 to \<726437 to \<8281008 to \<92821Learning disability4 to \<526200.0185 to \<638336 to \<727337 to \<8251218 to \<92830Sensory integration disorder4 to \<527100.515 to \<640136 to \<732017 to \<833328 to \<93010Cognitive impairment4 to \<526200.315 to \<636416 to \<731027 to \<832428 to \<92911ADHD4 to \<527010.285 to \<642116 to \<731117 to \<832428 to \<92722Mental retardation4 to \<527100.595 to \<642206 to \<733007 to \<837018 to \<93010Mild developmental delay4 to \<5171010.245 to \<6321016 to \<729407 to \<8271008 to \<92362Pervasive developmental disability4 to \<527010.145 to \<642016 to \<732007 to \<834228 to \<92802

\*P-value calculated using total who answered yes or no (excludes those indicating they don't know)

Table 4.Summarizes the use of services based on age groups.OutcomeOutcome response - NoOutcome response - YesAge groupORP-value95% CIClassroom services1434 to \<51.0026115 to \<61.970.350.47 -- 8.272676 to \<71.260.770.28 -- 5.6315207 to \<86.220.0111.51 -- 25.622558 to \<90.930.930.19 -- 4.50Individual therapy2714 to \<51.004205 to \<6\-\-\-\-\--3126 to \<71.740.660.15 -- 20.293347 to \<83.270.300.35 -- 31.043018 to \<90.900.940.05 -- 15.10Group therapy2714 to \<51.004115 to \<60.660.770.04 -- 10.983216 to \<70.840.910.05 -- 14.133537 to \<82.310.480.23 -- 23.513018 to \<90.900.940.05 -- 15.10Seeing a psychologist2534 to \<51.004025 to \<60.420.360.06 -- 2.672576 to \<72.330.270.54 -- 10.062987 to \<82.300.250.55 -- 9.612288 to \<93.030.140.71 -- 12.85

**[Glucocorticoid use and reported neurodevelopmental needs]{.ul}**

Of the 204 participants, 124 participants (60.8%) were on oral glucocorticoid. When cognitive domains were compared between glucocorticoid users and glucocorticoid non-users, there was no relationship between glucocorticoid use and any of the cognitive domains (Table 5). The utilization of classroom services or mental health professionals was also not significantly different between these glucocorticoid users and glucocorticoid non-users (data not shown). In addition, no significant difference in the total quality-of-life score or sub-scores was detected between these two groups (data not shown).

Table 5.Summarizes the relationship between neurodevelopmental and behavioral challenges and glucocorticoid use.Have you ever been diagnosed with-Cumulative lifetime steroid useNoYesDon\'t knowP-value\*Significant behavioral problems\<6 months801140.15≥ 6 months62170Depression\<6 months94010.45≥ 6 months7711Autism\<6 months89320.99≥ 6 months7720Speech delay\<6 months662720.20≥ 6 months48301Language impairment\<6 months791150.39≥ 6 months63133Learning disability\<6 months781070.38≥ 6 months66130Sensory integration disorder\<6 months89240.41≥ 6 months7342Cognitive impairment\<6 months83730.76≥ 6 months7143ADHD\<6 months88340.47≥ 6 months7153Mental retardation\<6 months92300.63≥ 6 months7711Mild developmental delay\<6 months682240.86≥ 6 months60180Pervasive developmental disability\<6 months89040.21≥ 6 months7423

\*P-value calculated using total who answered yes or no (excludes those indicating they don't know)

**[Neurodevelopmental needs based on *DMD* mutation location]{.ul}**

We compared the reported cognitive domains affected in the three subcategories of DMD study participants (dystrophin dp140(+), dystrophin dp140(-), and dystrophin dp140 intermediate). Several statistical associations were noted between the three subcategories of study participants, with differences between subcategories in domains of cognitive and language impairments, learning disability, and utilization of classroom services.

For those cognitive domains that showed a statistically significant relationship with DMD mutations affecting the dystrophin dp140 isoform (exon 45-50), further analysis using logistic regression showed that study participants in the dystrophin dp140 intermediate category were more alike those in the dystrophin dp140(+) category (Table 6). Most of the statistical differences detected were between the dystrophin dp140 intermediate and dystrophin dp140(-) categories.

Table 6.Summarizes the cognitive outcomes based on the three DMD genotype subgroups.Cognitive outcomeMutationResponse - NoResponse - YesORp-value95% CIP-value comparing Dp140Intermediate to Dp140NegativeBehavior problemsNegative34101.000.21Intermediate3730.280.070.07--1.09Positive4080.680.470.24--1.91Language impairmentNegative31111.000.59Intermediate3830.220.0310.06--0.87Positive4250.340.060.11--1.06Learning disabilityNegative33101.000.26Intermediate3810.090.0230.01--0.71Positive4240.310.070.09--1.09Classroom servicesNegative17191.000.49Intermediate3260.170.0010.06--0.50Positive36100.250.0040.10--0.65Cognitive impairmentNegative3671.00\-\--Intermediate390\-\-\-\-\--Positive4420.240.080.05--1.20

Dystrophin dp140 intermediate participants were significantly less likely to report affected cognitive domains than dystrophin dp140(-) participants. In the domains of cognitive impairment and behavioral problems, there was no statistical significance between the three groups. Participants in the dystrophin dp140 intermediate group were significantly less likely to have a diagnosis of significant language impairment (OR=0.22, 95% CI 0.06 -- 0.87) and learning disability (OR=0.09; 95% CI 0.01 -- 0.71). Further, a statistically significant relationship between the utilization of classroom services and DMD mutation subcategory, with both the dystrophin dp140(+) and dystrophin dp140 intermediate categories being less likely to utilize classroom services than those who were dystrophin dp140(-) (OR=0.17, 95%CI 0.06-0.5; OR=0.25, 95%CI 0.10-0.65, respectively). There were no statistically significant differences between the dystrophin dp140(+) and dystrophin dp140 intermediate categories in any of the cognitive domains. There were also no statistically significant differences in the utilization of mental health professionals or quality-of-life assessments between the three subcategories (data not shown).

**[Quality-of-life assessment]{.ul}**

Quality-of-life was assessed using the PedQoL questionnaire and a total of 141 (69%) care-givers completed the questionnaire. One questionnaire was completed per participant. Mean (±SD) sub-scores for physical, emotional, social, and school domains were all below 50 (41.9 ± 21.2, 25.4 ± 18.3, 34.2 ± 10.5, and 29.2 ± 20.0, respectively). The mean total score for all 141 participants was 33.9 ± 16.0 and ranged from 4.4 to 70.7 (Supplemental Table 6). None of the participant in the study scored the maximum score of 100.

Discussion
==========

In this report, we present data as assessed by the DNHS to support the prevalence of neurodevelopmental needs in young boys with DMD. To our knowledge, this is the first prospectively collected data of neurodevelopmental needs from a large well-characterized, internationally representative cohort of young boys with DMD. We also stratified boys with DMD mutations into three sub-categories based on DMD mutations likely to affect the dystrophin dp140 isoform to characterize in greater detail the neurodevelopmental needs in this cohort. By contrast, both Felisari et al.[@ref16] and Bardoni et al.[@ref17] evaluated cognitive impairment based on assessment of intellectual capacity through intelligence quotient, while our data is based on parent- or primary care-giver report.

Speech delay was the most commonly reported neurodevelopmental need in our cohort. Speech delay was reported by 33% of our respondents, and is consistent with reports of higher prevalence of speech delay in DMD[@ref7]^,^[@ref10]. Speech delay is a predictor of later education and classroom services utilization. Soim et al. describe that receiving speech therapy is statistically associated with an increased prevalence of grade repetition[@ref10]. Thus, speech delay in DMD has implications in the developmental trajectory of affected boys, and suggests that these children may need additional resources to achieve optimal educational outcomes. Such additional resources include earlier psycho-educational assessment in boys with DMD identified with speech delay. Recognition of early learning differences would potentially facilitate establishing appropriate school support and prevent grade repetition. Not only would it improve the quality of school experience for these children, it would also help improve long-term educational outcomes. Our collective experience as professionals engaged in the care of DMD families, psycho-educational testing often times, does not occur until age 7 or 8 years, thus delaying the care-givers and educators awareness of the unique neurodevelopmental needs in young boys with DMD. This lack of awareness may be the reason that parent-reported concerns were particularly more frequent in boys between the ages of 7 to less than 8 years in our cohort.

The reported prevalence of attention-deficit and autism that is described in our cohort is different from those reported from earlier studies. For example, Ricotti et al. evaluating boys with DMD of ages 5 to 17 years noted that the prevalence of autism spectrum was 21%[@ref21]. They used both a neurodevelopmental questionnaire and a structured diagnostic interview. Pane et al. found that nearly 32% of boys with DMD fulfilled criteria for attention deficit-hyperactivity using DSM-IV criteria. The mean age of their cohort was 12.6 years[@ref4]. Thus, the differences reported in our cohort is likely methodological in nature. Furthermore, the mean age of our cohort was 6.4 years, and full manifestations of attentional challenges and hyperactivity may not be fully manifest.

To our knowledge, there is limited data on the long-term educational and employment impact of cognitive needs in DMD. We note that parent-reported concerns were particularly frequent in boys between ages 7 to less than 8 years (Tables 4 and 5). Most of the study participants in our data are from developed countries, and age at school entry is approximately 5 years. We reason that as they transition from pre-school to primary school, neurodevelopmental needs may become increasingly apparent. This may be in addition possibly to the lack of awareness of the unique neurodevelopmental needs in this population by care-givers and educators.

School and emotional sub-scores scored among the lowest average sub-scores with PedsQoL, demonstrating that these two sub-domains may be most affected by disease burden in this cohort (Supplemental Table 6). While the exact reasons for these findings are unclear, our data suggests that neurodevelopmental and behavioral needs may influence school-related experiences in young children. Further detailed analyses in this area are warranted to understand the impact of neurodevelopmental needs in educational outcomes.

The use of glucocorticoids has been shown to be associated with behavioral and mood changes[@ref22]. In this young cohort of boys with DMD, we found that approximately 60% of them were on oral glucocorticoids at the time of entry to study. Consistent with other reports[@ref23]^,^[@ref24], we did not find a statistically significant association between reported neurodevelopmental concerns and glucocorticoid use. Population-based longitudinal data does support that evaluated longitudinally, glucocorticoid use is associated with behavioral difficulties in older boys with DMD[@ref5]. The cross-sectional nature of our data analysis and the younger age of our cohort may explain this difference with existent data.

Clinical and genetic heterogeneity in DMD has been well-described[@ref25]^,^[@ref26]^,^[@ref27] and it has previously been noted that cognitive outcomes may predict motor, cardiac and respiratory outcomes in DMD[@ref28]. Boys with DMD who had poor cognition, also had worse cardiac outcome, with two-thirds of these boys having cardiac involvement before age 12. This data suggests that overall health maintenance in DMD may be dictated in part by cognitive health, or a genetic modifier, or both.

Our study has some limitations. First, the DNHS was not designed to assess in detail the neurodevelopmental needs of this cohort. Therefore, there was no collection of objective psychometric data during the study. Existent data does suggest that neurodevelopmental needs of DMD are present even during infancy[@ref29]. Chieffo et al. report that young boys with DMD showed clear developmental concerns when followed prospectively[@ref30].

The second limitation of our study is that some of the recorded responses were ambiguous, and some parent- or care-giver reported concerns have overlapping features. For example, there was lack of distinction between "cognitive and language impairment" on the questionnaire. Neurodevelopmental needs may exist on a continuum and may overlap; for example, there may be co-existent speech delay and language impairment. Particularly in DMD, two or more neurodevelopmental disorders can co-exist, highlighting the overlap in developmental pathways affected. Despite these limitations, our data highlights the clear neurodevelopmental burden in this medically vulnerable population. Our data suggests that future studies in DMD should consider the use of standardized reports such as patient-reported outcome measures or the muscular dystrophy quality-of-life questionnaire. Further, specific recommendations in future studies in DMD should consider standardized assessment of cognitive ability.

Taylor et al. reported that the cumulative loss of multiple brain-specific dystrophin-isoforms may increase the burden of neurocognitive deficits in DMD[@ref31]. The existence of multiple brain-specific dystrophin isoform suggests a redundancy in some of its functions in the developing brain. We chose to particularly focus the analysis in DMD region exon 45-50 based on the current clinical and research priority to understand better the heterogeneity within this sub-group based on the available exon 51 skipping therapy, and recent published report on the structural and functional compromise to the developing brain due to DMD mutations that affect dystrophin dp140 isoform[@ref18].

Our data highlights a critical, yet often unmet medical need in this population. It is a widely held notion that cognitive impairments are irreversible in neurodevelopmental disorders. This notion is being challenged by the emergence of new scientific data that modulation of receptors can result in improvement of cognitive function[@ref32]. Our data provides a focal point on how future studies in DMD should aim to address neurodevelopmental needs more comprehensively through collection of objective psychometric data longitudinally. This approach will provide important scientific data to enable development of pragmatic interventions to improve educational and workplace integration for individuals with DMD, many of whom now have the capacity to attain independency as adults in society.

Supporting Information
======================

S1 TableDescription of cognitive outcomes at the baseline visit.Have you ever been diagnosed with...No\*YesDon\'t KnowTotal answeredSignificant behavioral problems142 (83.5%)28 (16.5%)4174Depression171 (99.4%)1 (0.6%)2174Autism166 (97.1%)5 (2.9%)2173Speech delay114 (66.8%)57 (33.3%)3174Language impairment142 (85.5%)24 (14.5%)8174Learning disability144 (86.2%)23 (13.8%)7174Sensory integration disorder162 (96.4%)6 (3.6%)6174Cognitive impairment154 (93.3%)11 (6.7%)6171ADHD159 (95.2%)8 (4.8%)7174Mental retardation169 (97.7%)4 (2.3%)1174Mild developmental delay128 (76.2%)40 (23.8%)4172Pervasive developmental disability163 (98.8%)2 (1.2%)6171

\*Percentages calculated using total who answered yes or no (excludes those indicating they don't know).

S2 TableDescription of therapy outcomes at the baseline visit.Have you ever had...NoIn the pastOccasionallyDaily or regularlyTotal answeredIndividual therapy163 (95.3%)3 (1.8%)2 (1.2%)3 (1.8%)171Group therapy165 (95.9%)4 (2.3%)1 (0.6%)2 (1.2%)172

S3 TableDescription of school related outcomes at the baseline visit.Have you ever had...No\*YesNot applicableDon\'t knowTotal answeredIEP or 504 plan65 (39.2%)65 (39.2%)36 (21.7%)3169Services in the classroom106 (62.7%)46 (27.2%)17 (10.1%)2171Part-time special education119 (71.3%)27 (16.2%)21 (12.6%)4171Full-time special education135 (81.8%)8 (4.9%)22 (13.3%)5170

\*Percentages calculated using total who answered yes, no, or not applicable (excludes those indicating they don't know)

S4 TableDescription of psychiatry use at the baseline visit.Have you ever seen a...NoYesTotal answeredPsychiatrist158 (94.1%)10 (6.0%)168

S5 TableDescription of psychology use at the baseline visit.Have you ever seen a...NeverWeeklyMonthlyQuarterlyAs neededTotal answeredPsychologist141 (83.4%)2 (1.2%)2 (1.2%)4 (2.4%)20 (11.8%)169

S6 TableDescription of PedsQL assessments at the baseline visit.PedsQOL scoreNMean ± SDMedian (min, max)Physical sub-score14141.9 ± 21.240.6 (0, 100)Emotional sub-score14125.4 ± 18.325 (0, 75)Social sub-score14134.3 ± 10.535 (0, 100)School sub-score13329.2 ± 20.025 (0, 80)Total score14133.9 ± 16.032.6 (4.4, 70.7)

\*Percentages calculated using total who answered yes or no (excludes those indicating they don't know)
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